Global speaker programmes
For patients to benefit from new medical innovations, HCPs need to access and understand the latest available data and clinical use of the product.
Feedback from HCPs shows that they prefer to learn about new data and clinical experience through peer-to-peer programmes with global expert practitioners who have direct experience with our medicines.
To help HCPs share new data on our products and understand their clinical use, in some cases we:
- make fair market value payments to global expert practitioners who speak about the new science behind selected GSK products, their associated diseases and clinical practice in promotional settings
- pay reasonable travel costs (except in the US) for an HCP to attend a GSK-organised standalone meeting to learn about data and clinical expertise.
- directly pay registration fees for HCPs to attend remote congress webinars/webcasts. We do not sponsor HCPs to attend local and international conferences.
This policy is limited to select products in certain countries around the world and controls and training are in place, including measures to track appropriate payment and use of external speakers.
Where legally permitted, we will report individual-level payments made each year to HCPs for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
Collaborating on clinical trials and research
Healthcare professionals (HCPs) help us identify potential volunteers for clinical trials, administer the investigational medicine or vaccine to patients, and monitor the results.
All HCPs who work with us on clinical trials have contracts and are paid for their work on these clinical trials. This payment covers their time, plus the cost of investigations they may need to carry out regarding the suitability of a patient and the effectiveness of the treatment.
We have a commitment to publicly disclose the research payments that are made to healthcare professionals and to their institutions for conducting clinical research.
Disclosure reports
- Outside of Europe and the US, we continue to support transparency as industry associations or governments establish specific guidelines for disclosure. Where legally permitted, we disclose annually individual level payments for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards in the markets where these activities take place. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
- In the US, we report our payments and other transfers of value to US Healthcare Professionals and US Healthcare Organisations we have worked with, in compliance with federal and state transparency laws. View the Federal CMS Open Payments data
- In Europe, we fully support and continue to implement the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfer of value from pharmaceutical companies to HCPs and HCOs. To affirm our commitment to the principles of the EFPIA Code of Practice we've signed this self-certification letter (PDF - 746kb).
- Argentina
- Austria
- Bahrain
- Belgium
- Bosnia and Herzegovina
- Brazil
- Bulgaria
- Chile
- Colombia
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Any engagement with a pharmaceutical company including zero payment engagements
- All R&D engagements by named disclosure
- Congress sponsorships (no amount disclosure)
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Kuwait
- Ireland
- Israel
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malaysia
- Malta
- Mexico
- Netherlands
- North Macedonia
- Norway
- Oman
- Philippines
- Poland
- Portugal
- Qatar
- Romania
- Russia
- Saudi Arabia
- Serbia and Montenegro
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Thailand
- Turkey
- Ukraine
- United Arab Emirates
- United Kingdom
As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices, GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK, in accordance with the terms of contracts with such third parties. Such services include activities such as speaking at a conference, providing advice as a member of an expert advisory board or as a consultant, as well as travel and accommodation expenses associated with those services.
In 2021, GSK made payments totaling ARS 22.505.278,81 to a total of 143 healthcare professionals.
| Year | Report |
|---|---|
| 2021 | PDF (235KB) |
Media enquiries:
Please contact Daniel Morelli, Comms & Government Affairs Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Austria in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Deutsch |
|---|---|---|---|
| 2021 | PDF (204KB) | PDF (751KB) | PDF (656KB) |
| 2020 | PDF (1.7MB) | PDF (116KB) | PDF (97KB) |
| 2019 | PDF (139KB) | PDF (119KB) | PDF (101KB) |
Media enquiries:
Please contact Mag. Barbara Masser-Mayerl, Communications Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid 4,725 BHD to a total number of 14 HCPs with an average payment of 338 BHD per HCP.
| Year | Report |
|---|---|
| 2021 | PDF (226KB) |
Media enquiries:
Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Belgium in line with the EFPIA code and pharma.be code, and to a note on the methodology used to set out the data in the report.
The significant presence of GSK Vaccines in Belgium, where the global centre for R&D (research & development) as well as the manufacturing site of vaccines, explain why some local collaborations with Healthcare Professionals and Organisations have an international dimension.
Media enquiries:
Please contact Elisabeth Van Damme
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Bosnia and Herzegovina in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Bosnian |
|---|---|---|---|
| 2021 | No transfer of values were made | ||
| 2020 | No transfer of values were made | ||
| 2019 | PDF (83KB) | PDF (147KB) | |
Media enquiries:
Please contact Office Headquarters
| Contact details | |
|---|---|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid R$ 1.015 milhão, to a total number of 142 HCPs with an average payment of R$ 7.148/HCP.
Media enquiries:
Please contact Gabriela Simões, Head of Communications Brazil
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Bulgaria in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note български |
|---|---|---|---|
| 2021 | PDF (116KB) | PDF (104KB) | PDF (102KB) |
| 2020 | PDF (142KB) | PDF (272KB) | PDF (119KB) |
| 2019 | PDF (135KB) | PDF (272KB) | PDF (121KB) |
Media enquiries:
Please contact Office Headquarters
| Contact details | |
|---|---|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid CLP $39,033,792 to a total number of 44 HCPs with an average payment of CLP $756,368./HCP.
| Year | Report |
|---|---|
| 2021 | PDF (199KB) |
Media enquiries:
Please contact Mariella Parodi Soza, Communications & Government Affairs Head, LATAM South Pacific Cluster
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid COP 160.733.320* to a total number of 30 HCPs with an average payment of COP 5.357.777/HCP.
* This amount does not include Colombian HCPs hired by other GSK subsidiaries and paid outside Colombia.
Media enquiries:
Please contact Juan Garcia, CGA Colombia Head
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Croatia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Hrvatski |
|---|---|---|---|
| 2021 | PDF (103KB) | PDF (105KB) | PDF (103KB) |
| 2020 | PDF (118KB) | PDF (125KB) | PDF (171KB) |
| 2019 | PDF (139KB) | PDF (201KB) | PDF (227KB) |
Media enquiries:
Please contact Office Headquarters
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Cyprus in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | No transfer of values were made | |
| 2020 | PDF (97KB) | PDF (98KB) |
| 2019 | PDF (100KB) | |
Media enquiries:
Please contact Office Headquarters
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Czech Republic in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Czech |
|---|---|---|---|
| 2021 | PDF (157KB) | PDF (21KB) | PDF (65KB) |
| 2020 | PDF (129KB) | PDF (23KB) | PDF (71KB) |
| 2019 | PDF (140KB) | PDF (23KB) | PDF (72KB) |
Media enquiries:
Please contact Miriam Kejzlarová, Communication Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
EFPIA has assessed the Danish legislation on disclosure (decree number L94/2013-14) to meet the requirements for transparency and has exempted Denmark from implementing the EFPIA Disclosure Code given the disclosures are already disclosed through the Danish Medicines Agency / Laegemiddelstyrelsen.
Legislation in Denmark requires HCPs to self-disclose:
Our disclosures in Denmark via Danish Medicines Agency / Laegemiddelstyrelsen include all transfers of value made by GSK to individual HCPs. Any payments to HCOs and hospitals in Denmark are disclosed on the Grants & Donations section on GSKPro and in a yearly report on the homepage of ENLI (The Ethical Comittee for the Pharmaceutical Industry).
Media enquiries:
Please contact Helle Hellberg, Head of External Affairs
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Estonia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Eesti |
|---|---|---|---|
| 2021 | PDF (99KB) | PDF (118KB) | PDF (97KB) |
| 2020 | PDF (102KB) | PDF (551KB) | PDF (487KB) |
| 2019 | PDF (111KB) | PDF (283KB) | PDF (557KB) |
Media enquiries:
Please contact Head Office
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Finland in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Suomeksi |
|---|---|---|---|
| 2021 | PDF (175KB) | PDF (145KB) | PDF (143KB) |
| 2020 | PDF (161KB) | PDF (130KB) | PDF (129KB) |
| 2019 | PDF (153KB) | PDF (166KB) | PDF (153KB) |
Media enquiries:
Please contact Anna Dammert
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for France in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Français |
|---|---|---|---|
| 2021 | PDF (94KB) | PDF (99KB) | PDF (118KB) |
| 2020 | PDF (92KB) | PDF (102KB) | PDF (82KB) |
| 2019 | PDF (87KB) | PDF (112KB) | PDF (95KB) |
Media enquiries:
Please contact Victoria Morel, Media Communication Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Germany in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Deutsch |
|---|---|---|---|
| 2021 | PDF (514KB) | PDF (153KB) | PDF (157KB) |
| 2020 | PDF (441KB) | PDF (498KB) | PDF (50KB) |
| 2019 | PDF (471KB) | PDF (49KB) | PDF (50KB) |
Media enquiries:
Please contact Dr. med. Guido Hermanns, Head of Communications
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Greece in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Ελληνικά |
|---|---|---|---|
| 2021 | PDF (413KB) | PDF (193KB) | PDF (187KB) |
| 2020 | PDF (268KB) | PDF (132KB) | PDF (125KB) |
| 2019 | PDF (277KB) | PDF (164KB) | PDF (154KB) |
Media enquiries:
Please contact Vasilia Papagiannopoulou - Government Affairs & Market Access Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Hungary in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Magyar |
|---|---|---|---|
| 2021 | PDF (107KB) | PDF (87KB) | PDF (108KB) |
| 2020 | PDF (120KB) | PDF (90KB) | PDF (107KB) |
| 2019 | PDF (120KB) | PDF (88KB) | PDF (116KB) |
Media enquiries:
Please contact Office Headquarters
| Contact details | |
|---|---|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid 11,540 KWD to a total number of 30 HCPs with an average payment of 385 KWD per HCP.
| Year | Report |
|---|---|
| 2021 | PDF (231KB) |
Media enquiries:
Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The link below will take you to our disclosures for Ireland in line with the EFPIA code and Irish Pharmaceutical Healthcare Association (IPHA) code, that we are making through IPHA.
http://www.transferofvalue.ie/
Media enquiries:
Please contact Niamh Mullen, Head of Communications and Government Affairs
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Israel in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | PDF (77KB) | PDF (112KB) |
| 2020 | PDF (120KB) | PDF (29KB) |
| 2019 | PDF (32KB) | PDF (79KB) |
Media enquiries:
Please contact Margalit Keren, Communications Manager
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Italy in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
A specific focus on 2021 VIIV Healthcare TOV in favour of Italian HCPs and HCOs in Italy is available on ViiV Healthcare Italy webpages.
| Year | Report | Methodological Note English | Methodological Note Italiano |
|---|---|---|---|
| 2021 | PDF (843KB) | PDF (121KB) | PDF (102KB) |
| 2020 | PDF (1.2MB) | PDF (120KB) | PDF (102KB) |
| 2019 | PDF (1.4MB) | PDF (114KB) | PDF (96KB) |
Media enquiries:
Please contact Massimo Ascani, External Communications Director
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
Please find latest local disclosure report combining data from different companies published by Latvian Health Inspectorate.
A distributor SIA TAMRO (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Latvia. GSK has given authorisation for SIA TAMRO (“Phoenix”) to report Transfers of Value made to HCPs / HCOs in Latvia by GSK and by ViiV Healthcare.
The links below will take you to our previous year’s disclosures for Latvia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Latviski |
|---|---|---|---|
| 2021 | Transfers of value available on the Latvian Health Inspectorate | ||
| 2020 | Transfers of value available on the Latvian Health Inspectorate | ||
| 2019 | PDF (113KB) | PDF (106KB) | PDF (142KB) |
Media enquiries:
Please contact Office Headquarters
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
New local disclosure report will be published on State Medicines Control Agency Lithuania website by August 1, 2022 for ToVs to HCPs, and by November 1, 2022 for ToVs to HCOs:
State Medicines Control Agency Lithuania website
A distributor UAB „Tamro“ (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Lithuania. GSK has given authorisation for UAB TAMRO (“Phoenix”) to report Transfers of Value made to HCPs / HCOs in Lithuania by GSK and by ViiV Healthcare.
R&D aggregate TOV report:
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2021 | PDF (92KB) |
| 2020 | EUR 212.900,33 |
The links below will take you to our previous years’ disclosures for Lithuania in line with the EFPIA code and IFPA, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Lietuvos |
|---|---|---|---|
| 2019 | PDF (114KB) | PDF (106KB) | PDF (160KB) |
| 2018 | PDF (111KB) | PDF (225KB) | PDF (331KB) |
Media enquiries:
Please contact Office Headquarters
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Luxembourg in line with the EFPIA code and APL code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Français |
|---|---|---|---|
| 2021 | PDF (96KB) | PDF (176KB) | PDF (101KB) |
| 2020 | PDF (98KB) | PDF (96KB) | PDF (101KB) |
| 2019 | PDF (99KB) | PDF (94KB) | PDF (98KB) |
Media enquiries:
Please contact Elisabeth Van Damme
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending / supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid RM 57,000 to a total number of 34 HCPs.
| Year | Report |
|---|---|
| 2021 | PDF (102KB) |
Media enquiries:
Please contact David Lin, Director, Communications, Government Affairs & Strategic Customer Solutions
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Malta in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 |
No transfer of values were made |
|
| 2020 | PDF (89KB) | PDF (92KB) |
| 2019 | PDF (90KB) | PDF (92KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid $7,079,128 MXN to a total number of 139 HCPs with an average payment of $50,929 MXN /HCP.
Media enquiries:
Please contact Emma Prian, Communications and Government Affairs
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for the Netherlands in line with the EFPIA code and Code for Pharmaceutical Advertising (the CGR), and to a note on the methodology used to set out the data in the report. Transfers of value for research and development are not part of the Transparency Register and is therefore listed separately for GSK Netherlands.
https://www.transparantieregister.nl/homepage/zoek-uw-zorgaanbieder
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2021 | PDF (11KB) |
| 2020 | PDF (11KB) |
| 2019 | PDF (11KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Tel: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for North Macedonia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report |
|---|---|
| 2021 |
No transfer of values were made |
| 2020 |
No transfer of values were made |
| 2019 |
No transfer of values were made |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Norway in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Norsk |
|---|---|---|---|
| 2021 | PDF (172KB) | PDF (103KB) | PDF (117KB) |
| 2020 | PDF (170KB) | PDF (104KB) | PDF (104KB) |
| 2019 | PDF (124KB) | PDF (101KB) | PDF (102KB) |
Media enquiries:
Please contact Line Storesund Rondan, Head of Government Affairs and Communication
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid 6,266 OMR to a total number of 8 HCPs with an average payment of 783 OMR per HCP.
| Year | Report |
|---|---|
| 2021 | PDF (220KB) |
Media enquiries:
Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our transfer of values to HCPs includes scientific sponsorships and honorariums for provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we paid a total of Php 911.4k to 31 HCPs.
Disclaimer: This is a demonstration of GSK's transparency commitments as a global organization based on its independent selection of in scope activities. As such, the values herein disclosed may vary from GSK Philippines Inc.'s declaration in compliance with the local legal disclosure requirements. Further, no data privacy rights of any HCP has been breached by the foregoing disclosure.
Media enquiries:
Please contact Richard Arboleda, Communications and Government Affairs Head
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Poland in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Polski |
|---|---|---|---|
| 2021 | PDF (260KB) | PDF (632KB) | PDF (640KB) |
| 2020 | PDF (232KB) | PDF (632KB) | PDF (640KB) |
| 2019 | PDF (194KB) | PDF (628KB) | PDF (636KB) |
Media enquiries:
Please contact Urszula Karniewicz
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
In Portugal, GSK strictly complies with the requirements of Portuguese national law (decree number 176/2006) to continuously publish details of all transfers of value with HCOs and HCPs within 30 working days after any payment is made. These disclosures are published and publicly available on the transparency website of Infarmed (Portugal‘s National Authority of Medicines and Health Products / Infarmed - Autoridade Nacional do Medicamento e Produtos de Saúde).
Our disclosures in Portugal via Infarmed include all transfers of value made by GSK to individual HCPs as well as HCOs as required under Portuguese national law.
Media enquiries:
Please contact João Duarte
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid 68,267 QAR to a total number of 20 HCPs with an average payment of 3,413 QAR per HCP.
| Year | Report |
|---|---|
| 2021 | PDF (226KB) |
Media enquiries:
Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Romania in line with the EFPIA code and the local legislation requirements as were specified in the Law no. 95/2006 and OMS 194/2015.
Transfers of value to healthcare professionals and organisations published on the ANMDMR website as per Law no. 95/2006 and OMS 194/2015:
A distributor EL PHARMA ROMANIA SRL (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Romania. Transfers of Value made to HCPs / HCOs are reported separately by the local Phoenix entity on Sponsorizari – Medicamente de uz uman – ANMDMR and should be considered together with transfers of value made by GSK directly.
| Year | EFPIA Research Aggregate Disclosure Report |
|---|---|
| 2021 | PDF (90KB) |
| 2020 | PDF (98KB) |
| 2019 | PDF (98KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Russia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Pусский |
|---|---|---|---|
| 2021 | PDF (209KB) | PDF (81KB) | PDF (141KB) |
| 2020 | PDF (159KB) | PDF (81KB) | PDF (141KB) |
| 2019 | PDF (209KB) | PDF (81KB) | PDF (141KB) |
Media enquiries:
Please contact Ekaterina Zamaratskikh
| Contact details | |
|---|---|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/supporting educational meetings, providing advice as a member of an advisory board or as a consultant, as well as travel and accommodation expenses associated with those services. GSK voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid 2,194,725 SAR (623,990 USD) to 1694 HCPs with an average payment of 1,296 SAR (368 USD) per HCP.
Media enquiries:
Please contact Hany Soliman, Country Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Serbia and Montenegro in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Srpski |
|---|---|---|---|
| 2021 | PDF (106KB) | PDF (104KB) | PDF (113KB) |
| 2020 | PDF (111KB) | PDF (122KB) | PDF (161KB) |
| 2019 | PDF (333KB) | PDF (145KB) | PDF (140KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Slovakia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
A distributor PHOENIX Zdravotnicke zasobovanie, a.s. (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Slovakia. Transfers of Value made to HCPs / HCOs are reported separately by the local Phoenix entity on https://www.nczisk.sk and should be considered together with transfers of value made by GSK directly.
| Year | Report | Methodological Note English | Methodological Note Slovak |
|---|---|---|---|
| 2021 | PDF (101KB) | PDF (125KB) | PDF (153KB) |
| 2020 | PDF (103KB) | PDF (71KB) | PDF (127KB) |
| 2019 | PDF (104KB) | PDF (73KB) | PDF (130KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Slovenia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Slovenščina |
|---|---|---|---|
| 2021 | PDF (101KB) | PDF (105KB) | PDF (104KB) |
| 2020 | PDF (1.5MB) | PDF (88KB) | PDF (99KB) |
| 2019 | PDF (116KB) | PDF (88KB) | PDF (99KB) |
Media enquiries:
Please contact Central Office
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Slovenia in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Español |
|---|---|---|---|
| 2021 | PDF (3.6MB) | PDF (110KB) | PDF (109KB) |
| 2020 | PDF (3.2MB) | PDF (109KB) | PDF (108KB) |
| 2019 | PDF (1.8MB) | PDF (117KB) | PDF (112KB) |
Media enquiries:
Please contact Comms Department
| Contact details | |
|---|---|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Sweden in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Svenska |
|---|---|---|---|
| 2021 | PDF (160KB) | PDF (110KB) | PDF (334KB) |
| 2020 | PDF (117KB) | PDF (111KB) | PDF (334KB) |
| 2019 | PDF (118KB) | PDF (111KB) | PDF (111KB) |
Media enquiries:
Please contact Håkan Sjöström, Medical Governance Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Switzerland in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English | Methodological Note Deutsch | Methodological Note Français |
|---|---|---|---|---|
| 2021 | PDF (195KB) | PDF (241KB) | PDF (251KB) | PDF (243KB) |
| 2020 | PDF (179KB) | PDF (30KB) | PDF (32KB) | PDF (32KB) |
| 2019 | PDF (175KB) | PDF (51KB) | PDF (52KB) | PDF (51KB) |
Media enquiries:
Please contact Urs Kientsch, Corporate Affairs Director or Manuel Mosimann, Communications Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid 102,639 GBP to a total number of 654 HCPs* with an average payment of 157 GBP/HCP.
*There might be duplication due to independent sponsorships.
Media enquiries:
Please contact Supattra Harncharoen, Corporate Affairs Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
We have pledged to disclose the transfer of value that we make as we work together with healthcare professionals. This includes services such as speaker service, participation / support in educational meetings, participation in the Advisory Board or Consulting, as well as accommodation and transportation costs associated with these services. At GSK, our decision to voluntarily publish the payments we pay to HCPs is part of our commitment to ensuring our high ethical standards and transparency in the conduct of our business.
In 2021, we paid 11,972,953.78 (TL) totally to the 1745 (number of HCPs) HCPs, and our average payment per Healthcare Professional was 6,861.29 (TL).
Media enquiries:
Please contact Zeynep Birgül, Brand Communications & Patient Relations Manager
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for Ukraine in line with the EFPIA code and APRaD, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | Disclosure suspended for 2021 | |
| 2020 | PDF (109KB) | PDF (126KB) |
| 2019 | PDF (112KB) | PDF (126KB) |
Media enquiries:
Please contact Tetiana Tkachenko, Tender and Price Manager, GSK Pharmaceuticals Ukraine or Maryna Kuzemko, 180 PRPA or Anna Dziuba, 180 PRPA
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
GSK is committed to disclosing the payments we make, as we work together with healthcare professionals. Our payments to HCPs include the provision of services such as giving a lecture, attending/ supporting educational meetings, providing advice as a member of an Advisory Board or as a Consultant, as well as travel and accommodation expenses associated with those services. GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices.
In 2021, we have paid 329,937 AED to a total number of 62 HCPs with an average payment of 5,322 AED per HCP.
| Year | Report |
|---|---|
| 2021 | PDF (292KB) |
Media enquiries:
Please contact Averyan Vasylyev, Medical Director
| Contact details | |
|---|---|
|
Tel: |
|
|
Email: |
|
As an EFPIA member, GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes sponsorship for travel and registration fees to attend medical congresses, HCP consultancy, fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
The links below will take you to our disclosures for United Kingdom in line with the EFPIA code, and to a note on the methodology used to set out the data in the report.
| Year | Report | Methodological Note English |
|---|---|---|
| 2021 | PDF (701KB) | PDF (149KB) |
| 2020 | PDF (613KB) | PDF (64KB) |
| 2019 | PDF (816KB) | PDF (187KB) |
Media enquiries:
Please contact UK Office
| Contact details | |
|---|---|
|
Email: |
|
